Dear Editor,

Hematological manifestations reported in SARS-CoV-2 infection mainly include lymphocytopenia as a poor prognosis factor \[[@CR1]\]. Thrombocytopenia can be associated with disseminated intravascular coagulation \[[@CR2]\] or immune process \[[@CR3]\]. Data regarding anemia are scarce and in line with a recent report on six patients with heterogeneous hemolytic anemia \[[@CR4]\], we herein report on two patients with SARS-CoV-2-related cold agglutinin disease (CAD).

Patient 1 {#FPar1}
=========

A 43-year-old woman was admitted after a 10-day course of asthenia, fever, cough, diarrhea, and dyspnea. Her medical history comprised obesity and untreated multiple sclerosis. Nasopharyngeal Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) confirmed SARS-CoV-2 infection. Chest computed tomography showed a typical severe interstitial pneumonia. Hemoglobin was normal upon admission (13.1 g/dL). A treatment with oxygen support and antibiotics (ceftriaxone and azithromycin for 3 days then tazocillin for 3 days) was started, with a rapid improvement of respiratory parameters. At day 6, hemoglobin levels dropped to 6.1 g/dL, with hemolytic features (low haptoglobin, elevated bilirubin, and lactate dehydrogenase (LDH) levels). The direct antiglobulin test (4+) was positive with the presence of cold agglutinins (Fig. [1](#Fig1){ref-type="fig"}). Etiological workup for hemolysis was negative. After poor initial transfusion efficiency, hemoglobin levels and hemolytic parameters improved.Fig. 1Evolution of the biological parameters of cold agglutinin-associated hemolysis. **a** Evolution of the biological parameters of hemolysis in patient 1; **b** evolution of the biological parameters of hemolysis in patient 2

Patient 2 {#FPar2}
=========

A 63-year-old man, with a medical history of hypertension, was admitted for severe acute respiratory syndrome in intensive care unit (ICU). In the last 2 weeks, he presented with fever, cough, and progressive worsening dyspnea. The nasopharyngeal RT-PCR confirmed a SARS-CoV-2 infection. The initial blood count showed a non-regenerative normocytic anemia (10.5 g/dL). As haptoglobin levels were unmeasurable (\< 0.08 g/L), contrasting with increased serum orosomucoid (2.35 g/L), a hemolytic process was suspected and the direct antiglobulin test was positive (C3 \[4+\] and IgG \[2+\]) with cold agglutinins (Fig. [1](#Fig1){ref-type="fig"}). At day 6 of hospitalization, hemoglobin level decreased to 8.2 g/dL. Etiological workup was negative. Hemoglobin improved within 9 days along with clinical improvement.

We here report two supplemental cases of SARS-CoV-2-associated autoimmune hemolytic anemia with cold agglutinins which seems to be a rare but nevertheless real complication of this condition. CAD was previously reported in association with viral infections and *Mycoplasma pneumonia* infection. The pathophysiological mechanism might be related to an antigen cross-reaction with red blood cell secondary to molecular mimicry, as with *Influenzae* disease \[[@CR5]\]. A drug-induced CAD was considered uncommon \[[@CR6]\].

We believe that a more extensive investigation of anemia in SARS-CoV2 patients, including the appraisal of hemolytic patterns might be useful for the detection of other cases of CAD and appropriate management of anemia during SARS-CoV2-infection.
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